Market capitalization | $9.53m |
Enterprise Value | $7.61m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.10 |
P/S ratio (TTM) P/S ratio | 0.13 |
P/B ratio (TTM) P/B ratio | 0.32 |
Revenue growth (TTM) Revenue growth | -25.89% |
Revenue (TTM) Revenue | $75.48m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Aytu BioScience Inc:
1 Analyst has issued a forecast Aytu BioScience Inc:
Sep '24 |
+/-
%
|
||
Revenue | 75 75 |
26%
26%
|
|
Gross Profit | 47 47 |
20%
20%
|
|
EBITDA | 6.17 6.17 |
290%
290%
|
EBIT (Operating Income) EBIT | -1.53 -1.53 |
87%
87%
|
Net Profit | -6.25 -6.25 |
74%
74%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
Head office | United States |
CEO | John Donofrio |
Founded | 2002 |
Website | www.aytubio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.